Form 4 for CTNM Contineum Therapeutics, Inc.
Accepted 2024-08-14 00:00:00 ET · period of report 2024-08-13 · accession 0001437749-24-026903 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-14 | 2024-08-13 | CTNM | Huhn Stephen L. | CMO, SVP, Clinical Dev | M - OptEx | $1.01 | +12.8K | 12.8K | New | +$12.9K |
| D | 2024-08-14 | 2024-08-13 | CTNM | Huhn Stephen L. | CMO, SVP, Clinical Dev | M - OptEx | $0.00 | -12.8K | 161.4K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-08-13 | M | A | 12,800 | $1.01 | 12,800 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-08-13 | M | D | 12,800 | $0.00 | 161,394 | D | $1.01 · — to 2030-02-24 | 12,800 Class A Common Stock | (F2) Options granted under the Issuer's 2012 Equity Incentive Plan. The option is fully vested. |